GlobeNewswire by notified

H1 2020 Financial Information

Share


  • Cash and cash equivalents at €52.2m as at June 30, 2020

Daix (France), July 6, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of June 30, 2020.

As of June 30, 2020, Inventiva’s cash and cash equivalents stood at €52.2 million compared to €46.9 million as of March 31, 2020 and €35.8 million as of December 31, 2019.

Inventiva’s net cash flow amounted to €16.4 million in the six months ended June 30, 2020 compared to (€19.6) million in the first half of 2019. Net cash used in operating activities was (€10.7) million and (€18.7) million in the first half of 2020 and 2019, respectively. Net cash provided by (used in) financing activities was €28.1 million and (€0.1) million in the first half of 2020 and 2019, respectively. 

The Company believes that its cash and cash equivalents as of June 30, 2020 will be sufficient to fund its operating activities into the third quarter of 2021.

***

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012). www.inventivapharma.com


Contacts

Inventiva
Frédéric Cren
Chairman & CEO
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick Group
Yannick Tetzlaff / Tristan Roquet Montegon / 
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513 1284 


Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical trials, clinical trial data releases, clinical development plans and anticipated future activities of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, or that candidates will receive the necessary regulatory approvals. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates.Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release.Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document filed with the Autorité des marchés financiers (AMF) on June 19, 2020, available on the websites of Inventiva (www.inventivapharma.com) and AMF (www.amf-france.org),  for additional information in relation to such factors, risks and uncertainties.

Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 202328.3.2024 13:30:00 CET | Pressemelding

AB Traction: Traction publicerar årsredovisningen och årsberättelsen för 2023 Tractions årsredovisning och årsberättelse för 2023 är nu offentliggjorda och finns tillgängliga på bolagets webbplats, www.traction.se Den tryckta versionen av årsberättelsen kan beställas genom e-post till post@traction.se. AB Traction Petter Stillström Verkställande direktör Tel: 08-506 289 00 DENNA INFORMATION ÄR SÅDAN INFORMATION SOM AB TRACTION ÄR SKYLDIGT ATT OFFENTLIGGÖRA ENLIGT LAGEN OM VÄRDEPAPPERSMARKNADEN. INFORMATIONEN LÄMNADES FÖR OFFENTLIGGÖRANDE DEN 28 MARS 2024, KL. 13.30 CET. Bilagor Traction Årsredovisning 2023traction-2023-12-31-svTraction Årsberättelse 2023

Webtel.mobi publishes a detailed article on why the US Dollar is not under threat as Global Reserve Currency, nor a consideration for Global Financial Reform28.3.2024 13:00:46 CET | Press release

NEW YORK and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Global Telephony Provider Webtel.mobi has published a detailed article describing the real issue and remedy for achievement of Global Financial Reform, required to end the regular “Boom and Bust” cycles. Additionally, a public version of the article follows below Speculation as to the potential ending of the US Dollar’s reign as Global Reserve Currency – or the necessity of that – are both misplaced, according to the Global Telecommunications Company Webtel.mobi. This is, it says, because it is not a Global Currency (any one of them) that creates any global imbalances, weighted advantages or potential reform solutions. It is rather the Global System over which all currencies are transacted that creates all global imbalances, weighted advantages or potential reform solutions. The current Global System is relatively young. It came into being after the end of World War Two, and was provided to the world (or imposed on the world – dep

Digitalist Group Plc has published Financial Statements of 2023, Report by the Board of Directors, Auditor’s Report, Corporate Governance Statement and Remuneration Report28.3.2024 13:00:00 CET | Press release

Digitalist Group Plc Stock Exchange Release 28 March 2024 at 14:00 Digitalist Group Plc has published Financial Statements of 2023, Report by the Board of Directors, Auditor’s Report, Corporate Governance Statement and Remuneration Report Digitalist Group Plc has published the Financial Statements of 2023, the Report by the Board of Directors, the Auditor’s Report, the Corporate Governance Statement and the Remuneration Report in company’s internet pages mentioned below: The financial statements of 2023, which include the Board of Directors' report and the Auditor's report, are published at https://investor.digitalistgroup.com/investor/financial/financial-statements. The Corporate Governance Statement is published at https://investor.digitalistgroup.com/investor/governance. The Remuneration Report is published at https://investor.digitalistgroup.com/investor/governance/remuneration. The Financial Statements of 2023 which include the Board of Directors' report and the Auditor's report,

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors28.3.2024 13:00:00 CET | Press release

David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia have resigned their seats on the company’s board of directors, effective March 29, 2024. David Norton, lead independent director on the Compass board of directors, will become interim chair. Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle. “When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways. “The comp

Allied Industrial Partners-Backed CES Power Acquires ABird/Apex Power Solutions28.3.2024 12:45:10 CET | Press release

11th Bolt-on Acquisition Expands CES Power’s Global Presence Providing Significant Scale in the U.K. and Europe MEMPHIS, Tenn. and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- CES Power LLC (“CES Power”), a leading global provider of sustainable mobile power generation, distribution, temperature control and technology solutions for the largest and most complex projects and events, today announced that it has acquired ABird Limited and Apex Generators Limited (“ABird/Apex” or “the Company”), a U.K. supplier of portable power for industrial, corporate and event use. The acquisition was made through CES Power’s global division, CES Global LLC (“CES Global”), which acquired ABird/Apex from U.K. tool and equipment rental and services company HSS Hire Group Plc (LSE: HSS). CES Power is backed by industrial-focused private equity firm Allied Industrial Partners (“Allied”). This strategic acquisition will expand CES Global’s capacity in the U.K. and Ireland while helping to accelerate its growth

HiddenA line styled icon from Orion Icon Library.Eye